image
Healthcare - Medical - Devices - NASDAQ - US
$ 16.62
2.47 %
$ 737 M
Market Cap
-72.26
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AXGN stock under the worst case scenario is HIDDEN Compared to the current market price of 16.6 USD, AxoGen, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AXGN stock under the base case scenario is HIDDEN Compared to the current market price of 16.6 USD, AxoGen, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AXGN stock under the best case scenario is HIDDEN Compared to the current market price of 16.6 USD, AxoGen, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AXGN

image
$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
187 M REVENUE
17.81%
-3.29 M OPERATING INCOME
84.68%
-9.96 M NET INCOME
54.12%
4.54 M OPERATING CASH FLOW
179.34%
-10.3 M INVESTING CASH FLOW
-53.48%
2.29 M FINANCING CASH FLOW
17.20%
49.4 M REVENUE
1.56%
1.93 M OPERATING INCOME
709.81%
450 K NET INCOME
124.22%
8.74 M OPERATING CASH FLOW
123.92%
-813 K INVESTING CASH FLOW
83.74%
970 K FINANCING CASH FLOW
69.58%
Balance Sheet AxoGen, Inc.
image
Current Assets 99.2 M
Cash & Short-Term Investments 33.5 M
Receivables 24.1 M
Other Current Assets 41.6 M
Non-Current Assets 105 M
Long-Term Investments 0
PP&E 98.9 M
Other Non-Current Assets 5.58 M
16.43 %11.83 %20.43 %48.56 %Total Assets$203.7m
Current Liabilities 30.6 M
Accounts Payable 8.01 M
Short-Term Debt 1.97 M
Other Current Liabilities 20.6 M
Non-Current Liabilities 69.2 M
Long-Term Debt 66.7 M
Other Non-Current Liabilities 2.49 M
8.02 %20.67 %66.84 %Total Liabilities$99.8m
EFFICIENCY
Earnings Waterfall AxoGen, Inc.
image
Revenue 187 M
Cost Of Revenue 45.4 M
Gross Profit 142 M
Operating Expenses 145 M
Operating Income -3.29 M
Other Expenses 6.68 M
Net Income -9.96 M
200m200m180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)187m(45m)142m(145m)(3m)(7m)(10m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.79% GROSS MARGIN
75.79%
-1.75% OPERATING MARGIN
-1.75%
-5.32% NET MARGIN
-5.32%
-9.59% ROE
-9.59%
-4.89% ROA
-4.89%
-1.88% ROIC
-1.88%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AxoGen, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -9.96 M
Depreciation & Amortization 7.84 M
Capital Expenditures -4.52 M
Stock-Based Compensation 15.9 M
Change in Working Capital 0
Others -9.24 M
Free Cash Flow 11 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AxoGen, Inc.
image
AXGN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership AxoGen, Inc.
image
Sold
0-3 MONTHS
365 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer. seekingalpha.com - 1 month ago
Axogen, Inc. To Host Analyst & Investor Day on March 4th ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern. globenewswire.com - 1 month ago
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. globenewswire.com - 1 month ago
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 months ago
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 2 months ago
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Craig Swandal, experienced medical device manufacturing executive, joins leadership team Craig Swandal, experienced medical device manufacturing executive, joins leadership team globenewswire.com - 2 months ago
Axogen: Well Placed To Capitalize Growth At Higher Multiples Axogen: Well Placed To Capitalize Growth At Higher Multiples seekingalpha.com - 3 months ago
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 3 months ago
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year. zacks.com - 3 months ago
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 4 months ago
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 4 months ago
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer. seekingalpha.com - 5 months ago
8. Profile Summary

AxoGen, Inc. AXGN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 737 M
Dividend Yield 0.00%
Description AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Contact 13631 Progress Boulevard, Alachua, FL, 32615 https://www.axogeninc.com
IPO Date Dec. 17, 1986
Employees 451
Officers Mr. Harold D. Tamayo M.B.A. Vice President of Finance & Investor Relations Mr. Erick DeVinney Chief Innovation Officer Mr. Marc A. Began Executive Vice President, General Counsel & Chief Compliance Officer Mr. Craig A. Swandal Vice President of Operations Mr. Jens Schroeder Kemp Chief Marketing Officer Ms. Doris Quackenbush Vice President of Sales Mr. Michael D. Dale President, Chief Executive Officer & Director Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer Ms. Karen Zaderej Advisor